Archer Aviation IncArticle highlights new autonomous models for defense and commercial use, but stock has fallen 38% this year; no clear positive or negative catalyst.
The Motley Fool identifies Archer Aviation, CRISPR Therapeutics, and e.l.f. Beauty as mid-cap growth stocks with significant long-term upside. Archer Aviation, with a market cap of roughly $3.6 billion, is developing electric vertical take-off and landing aircraft and recently unveiled new autonomous models for defense and commercial use, though its stock has fallen 38% this year. CRISPR Therapeutics, valued at around $4.5 billion, is rolling out its gene therapy Casgevy for sickle cell disease and beta thalassemia, priced at $2.2 million per one-time treatment, while posting a net loss of $123 million in the first quarter. e.l.f. Beauty, with a valuation of $4.9 billion, reported net sales of $1.6 billion and adjusted net income of $185.9 million in its latest fiscal year, but its stock has declined 30% over the past 12 months amid tariff concerns.
Archer Aviation IncArticle highlights new autonomous models for defense and commercial use, but stock has fallen 38% this year; no clear positive or negative catalyst.
Crispr Therapeutics AGArticle mentions Casgevy rollout for sickle cell disease and beta thalassemia, but also notes a net loss of $123 million in Q1; mixed outlook.
ELF Beauty IncStock has declined 30% over the past 12 months amid tariff concerns.